Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 19:11:2909-12.
doi: 10.2147/NDT.S87359. eCollection 2015.

Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases

Aynur Pekcanlar Akay  1 , Gamze Capa Kaya  2 , Burak Baykara  1 , Yusuf Demir  2 , Handan Özek  1 , Sevay Alsen  1 , Mine Sencan Eren  2 , Neslihan Inal Emiroglu  1 , Turkan Ertay  2 , Yesim Ozturk  3 , Suha Miral  1 , Hatice Durak  2 , Evren Tufan  3
Affiliations

Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases

Aynur Pekcanlar Akay et al. Neuropsychiatr Dis Treat. .

Abstract

Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement.

Keywords: SLC6A3 protein; dopamine; human; neuroimaging; noradrenaline; pilot study; pragmatic clinical trial.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tc-99m TRODAT-1 SPECT image of one of the patients before (A) and after (B) treatment with atomoxetine.
See this image and copyright information in PMC

References

    1. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313–1323. - PubMed
    1. La Fougère C, Krause J, Krause KH, et al. Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl Med Commun. 2006;27(9):733–737. - PubMed
    1. Heal DJ, Smith SL, Kulkarni RS, Rowley HL. New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav. 2008;90:184–197. - PubMed
    1. Arnsten AF. Toward a new understanding of attention-deficit/hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs. 2009;23(Suppl 1):33–41. - PubMed
    1. Del’Guidice T, Lemasson M, Etiévant A, et al. Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice. Psychopharmacology (Berl) 2014;231(1):109–122. - PubMed

LinkOut - more resources